Alzheimer’s Research Program Transforming Diagnosis Award
ID: 358722Type: Posted
Overview

Buyer

Dept. of the Army -- USAMRAA (DOD-AMRAA)

Eligible Applicants

Unrestricted

Funding Category

Science and Technology and other Research and Development

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/358722
Timeline
    Description

    The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the Alzheimer's Research Program Transforming Diagnosis Award to support innovative research aimed at enhancing the diagnosis and prognosis of Alzheimer's disease and related dementias (AD/ADRD). This grant opportunity encourages community collaboration and requires the submission of preliminary data, with a focus on addressing barriers to effective dementia diagnosis. With an estimated total program funding of $3.2 million, the program anticipates awarding two grants, with funding caps set at $1.5 million for single Principal Investigator (PI) proposals and $1.7 million for those utilizing the Career Initiation or Transition Partnership Option. Interested applicants must submit a pre-application by June 12, 2025, followed by a full application due by August 29, 2025; for further inquiries, contact the CDMRP Help Desk at help@eBRAP.org or call 301-682-5507.

    Point(s) of Contact
    help@eBRAP.org
    Files
    Title
    Posted
    FY25.pdf
    The Fiscal Year 2025 Department of Defense Alzheimer’s Research Program (AZRP) outlines three primary award mechanisms aimed at advancing research related to Alzheimer’s disease and traumatic brain injury. Each mechanism targets independent investigators at varying career levels through single Principal Investigator (PI) options or partnering PI options, emphasizing community collaboration and specific guidelines for research methodologies. 1. **Transforming Diagnosis Award:** This award supports research to enhance diagnosis and prognosis of Alzheimer’s-related conditions in military personnel. The maximum funding is $1.5 million (or $1.7 million for Career Initiation or Transition investigators), with applications due by August 29, 2025, following a pre-proposal due on June 12, 2025. 2. **Transforming Research Award:** This mechanism funds studies aimed at reducing the risk or preventing Alzheimer’s development, particularly related to traumatic brain injury, with a budget cap of $1 million. Key requirements include the necessity for preliminary data and a focus on community collaboration, with similar deadlines as the Transforming Diagnosis Award. 3. **Transforming Care Award:** Focused on person-centered research, this award allows for clinical trials and requires a funding limit of $1.6 million (or $1.8 million for CIT), along with collaboration and preliminary data submission. All applications require initial pre-proposals submitted by June 12, 2025, before full applications due by August 29, 2025. This initiative illustrates the federal commitment to improving clinical approaches and outcomes for individuals affected by Alzheimer’s and related conditions.
    HT942525AZRPTrDA.pdf
    The Department of Defense (DOD) is announcing the FY25 Alzheimer’s Research Program's Transforming Diagnosis Award, aimed at enhancing diagnosis and prognosis of Alzheimer’s disease and related dementias (AD/ADRD). With a funding pool of approximately $3.2 million, the program intends to support innovative research projects, allowing for applications under a single Principal Investigator (PI) or a Career Initiation or Transition Partnership Option. The funding caps are set at $1.5 million for single PI proposals and $1.7 million for partnered efforts, with a maximum performance period of four years. Eligible applicants include both extramural and intramural organizations, with specific requirements for PIs at various career stages. Community collaboration is mandated, ensuring projects reflect the needs of AD/ADRD communities. Submissions undergo a two-step application process — a pre-application followed by a full application for invited applicants, with the latter evaluated on criteria such as impact, research strategy, and progression plans. The award emphasizes addressing barriers to dementia diagnosis and prognosis with substantial preliminary data required. Projects cannot involve clinical trials or animal studies; instead, previous studies or patient data must form the basis for new research. This initiative represents a critical step in advancing the understanding and management of Alzheimer’s and related conditions, enhancing quality of life for affected individuals and their families.
    Similar Opportunities
    Small Research Grant Program for the Next Generation of Researchers in AD/ADRD Research (R03 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Aging (NIA), is offering a Small Research Grant Program (R03) aimed at fostering the next generation of researchers in Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). This program supports innovative projects that enhance understanding, diagnosis, treatment, and care strategies for AD/ADRD, while also promoting workforce diversity and addressing health disparities in this field. Grants of up to $100,000 for a duration of two years are available, with a total of 12 awards expected for fiscal year 2024, amounting to $1.8 million in funding. Interested applicants must be affiliated with eligible organizations and are encouraged to submit their applications by March 16, 2026, with inquiries directed to grantsinfo@nih.gov for further information.
    Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional)" aimed at advancing exploratory research in Alzheimer's disease (AD) and related dementias (ADRD). This initiative invites applications for innovative methodologies, animal models, and techniques that require preliminary data, with a focus on addressing health disparities among under-resourced populations. The program emphasizes the importance of interdisciplinary research to combat the public health crisis posed by AD and ADRD, with a maximum funding amount of $275,000 available over two years. Interested applicants must submit their proposals by November 16, 2027, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Translational Bioinformatics and Experimental Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimers Disease and Related Dementias (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity aimed at advancing drug repositioning and combination therapy development for Alzheimer's Disease (AD) and related dementias (ADRD). This initiative invites applications that utilize mouse models to conduct rigorous preclinical testing of FDA-approved drugs or investigational compounds, with the goal of establishing proof of concept for effective treatment strategies. Given the historical challenges in developing successful AD therapies, this program emphasizes a systematic approach and encourages collaboration between academia and industry to enhance research rigor and reproducibility. Applicants may receive up to $1 million annually, with a total funding pool of $6 million available for 4-5 awards. The application deadline is May 7, 2028, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Alzheimer's Drug-Development Program (U01 Clinical Trial Optional) to support the preclinical and early-stage clinical development of innovative drug candidates aimed at preventing or treating Alzheimer's disease (AD). This funding opportunity focuses on activities such as medicinal chemistry, pharmacokinetics, formulation development, and initial Phase I clinical testing, addressing the urgent public health challenge posed by AD, which currently affects approximately 6.7 million individuals in the U.S. Eligible applicants include a diverse range of organizations, with a funding ceiling of $1.5 million per year, and the application process is set to begin in January 2025, with a closing date of November 5, 2027. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Institutional Training Programs to Advance Translational Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (T32 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Institutional Training Programs to Advance Translational Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (T32 Clinical Trial Not Allowed)." This initiative aims to develop a diverse, interdisciplinary workforce capable of conducting translational research on AD and ADRD, supporting training programs for predoctoral and postdoctoral researchers with varied educational backgrounds. The program emphasizes the importance of interdisciplinary collaboration and aims to enhance understanding and treatment of aging-related health issues. NIH plans to award an estimated 3-5 grants annually over the next three years, with a total budget of $2.7 million, and applications are due by September 25, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Institutional Training Programs to Advance Translational Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (T32 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Institutional Training Programs to Advance Translational Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD)" aimed at developing a diverse and interdisciplinary workforce for translational research in this critical health area. The initiative invites eligible institutions to create training programs for predoctoral and postdoctoral researchers, focusing on enhancing skills in data science, disease biology, and drug discovery, while not permitting independent clinical trials. With an anticipated budget of approximately $2.7 million annually for 3-5 awards over fiscal years 2025-2027, applications are due by September 25, 2026, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Alzheimer's Disease Programs Initiative (ADPI) - State and Community Grant Program
    Administration for Community Living
    The Administration for Community Living is offering the Alzheimer's Disease Programs Initiative (ADPI) - State and Community Grant Program, aimed at enhancing dementia-capable home and community-based service systems. This opportunity includes two application options: Grants to States, which focus on creating and sustaining state-level dementia-capable systems, and Grants to Communities, which support community-based organizations in addressing specific service gaps for individuals living with Alzheimer's disease and related dementias. With an estimated total program funding of $10 million, the program anticipates awarding 12 grants, with individual awards ranging from $850,000 to $1 million. Interested applicants can find more information and contact Kari Benson at aoa.oaa@acl.hhs.gov or by phone at 202-795-7389, with applications due by March 17, 2026.
    Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel Therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD)." This initiative aims to streamline the early-stage evaluation of promising pharmacological interventions by bundling independent protocols for phase 1 clinical trials with phase 1b/phase 2a trials, focusing on non-amyloid/non-tau mechanisms that address cognitive and neuropsychiatric symptoms across various stages of the disease. The program is particularly significant given the rising prevalence of Alzheimer's and the associated economic burden, emphasizing the need for innovative treatments as the aging population grows. Eligible applicants include a diverse range of organizations, such as higher education institutions and community-based organizations, with proposals due by November 19, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-226.html.
    Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the R21 exploratory research grant focused on understanding neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD) and related dementias (ADRD). This funding opportunity aims to enhance knowledge of the neurobiological and behavioral mechanisms underlying symptoms such as aggression, anxiety, and agitation, which significantly impact patient care and outcomes. The initiative is part of a broader national effort to address the complexities of Alzheimer's care, with funding capped at $275,000 over two years, and applications opening on January 16, 2025. Interested applicants can find more information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for research on current topics in Alzheimer's disease (AD) and its related dementias (ADRD) through the R01 Clinical Trial Optional grant program. This initiative aims to support innovative research that addresses significant biomedical, social, and behavioral aspects of aging, with a focus on inclusivity and diversity in participant recruitment. Given the projected rise in expenditures for AD-related care, which could exceed $1 trillion by 2050, this funding is critical for advancing understanding and treatment of dementia-related challenges. Interested applicants can find more information and submission guidelines at the NIH grants website, with applications due by November 5, 2027, and no specific budget limits outlined.